Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2021

Open Access 01-12-2021 | Acromegaly | Case report

Acromegaly and non‐parathyroid hormone‐dependent hypercalcemia: a case report and literature review

Authors: Shaomin Shi, Lan Zhang, Yerong Yu, Chun Wang, Jianwei Li

Published in: BMC Endocrine Disorders | Issue 1/2021

Login to get access

Abstract

Background

Hypercalcemia associated with acromegaly is mostly parathyroid hormone (PTH)-dependent, being caused by parathyroid hyperplasia or adenoma, which are common in individuals with multiple endocrine adenomatosis-1 (MEN-1). The rare occurrence of non-PTH-dependent hypercalcemia associated with acromegaly is attributable to complex factors involving increased intestinal calcium absorption, enhanced bone calcium release, and reduced urinary calcium elimination. Although patients with acromegaly often have mild hyperphosphatemia and hypercalciuria, clinically significant hypercalcemia is extremely rare.

Case presentation

Here we present a case of non-PTH-dependent hypercalcemia associated with a growth hormone- (GH) and prolactin- (PRL) co-secreting pituitary macroadenoma. A 37-year-old Chinese man presented with a 6-year history of increasing ring and shoe sizes and was referred to the West China Hospital of Sichuan University for treatment of acromegaly. Pituitary magnetic resonance imaging (MRI) showed a 2.0 × 1.7 × 1.9 cm macroadenoma. Laboratory examinations revealed high serum concentrations of GH and PRL with mild hypercalcemia, hyperphosphatemia, hypercalciuria, inhibited PTH concentration, and increased bone turnover markers. Administration of cabergoline together with somatostatin resulted in sharp decreases in his GH, PRL, and serum and urinary calcium concentrations. These values were further reduced 5 months later and his PTH and bone turnover markers gradually returned to within the normal range.

Conclusions

Mild hyperphosphatemia and hypercalciuria are common in individuals with acromegaly and deserve attention because they may contribute to osteoporosis and urolithiasis. However, overt hypercalcemia is rare in such individuals. It is usually attributable to a coexisting parathyroid hyperplasia or adenoma, rarely being non-PTH-dependent. In such cases, the hypercalcemia is attributable to excessive PRL and hypogonadism and reverses with remission of acromegaly.
Literature
1.
go back to reference Shah R, Licata A, Oyesiku NM, Ioachimescu AG. Acromegaly as a cause of 1,25-dihydroxyvitamin D-dependent hypercalcemia: case reports and review of the literature. Pituitary. 2012;15(Suppl 1):17–22.CrossRef Shah R, Licata A, Oyesiku NM, Ioachimescu AG. Acromegaly as a cause of 1,25-dihydroxyvitamin D-dependent hypercalcemia: case reports and review of the literature. Pituitary. 2012;15(Suppl 1):17–22.CrossRef
2.
go back to reference Ueda M, Inaba M, Tahara H, Imanishi Y, Goto H, Nishizawa Y. Hypercalcemia in a patient with primary hyperparathyroidism and acromegaly: distinct roles of growth hormone and parathyroid hormone in the development of hypercalcemia. Intern Med (Tokyo Japan). 2005;44:307–10.CrossRef Ueda M, Inaba M, Tahara H, Imanishi Y, Goto H, Nishizawa Y. Hypercalcemia in a patient with primary hyperparathyroidism and acromegaly: distinct roles of growth hormone and parathyroid hormone in the development of hypercalcemia. Intern Med (Tokyo Japan). 2005;44:307–10.CrossRef
3.
go back to reference Thakker RV. Multiple endocrine neoplasia type 1 (MEN1). Best practice & research Clinical endocrinology & metabolism. 2010;24:355 – 70. Thakker RV. Multiple endocrine neoplasia type 1 (MEN1). Best practice & research Clinical endocrinology & metabolism. 2010;24:355 – 70.
4.
go back to reference Manroa P, Kannan S, Hatipoglu B, Licata A. Hypercalcemia and acromegaly–clarifying the connections. A case report and review of the literature. Endocrine practice. 2014;20:e86–90.CrossRef Manroa P, Kannan S, Hatipoglu B, Licata A. Hypercalcemia and acromegaly–clarifying the connections. A case report and review of the literature. Endocrine practice. 2014;20:e86–90.CrossRef
5.
6.
go back to reference Constantin T, Tangpricha V, Shah R, et al. Calcium and Bone Turnover Markers in Acromegaly: A Prospective, Controlled Study. J Clin Endocrinol Metab. 2017;102:2416–24.CrossRef Constantin T, Tangpricha V, Shah R, et al. Calcium and Bone Turnover Markers in Acromegaly: A Prospective, Controlled Study. J Clin Endocrinol Metab. 2017;102:2416–24.CrossRef
7.
go back to reference Hermans MM, Lips CJ, Bravenboer B. Growth hormone overproduction in a patient with multiple endocrine neoplasia type I. Journal of internal medicine. 2000;248:525–30.CrossRef Hermans MM, Lips CJ, Bravenboer B. Growth hormone overproduction in a patient with multiple endocrine neoplasia type I. Journal of internal medicine. 2000;248:525–30.CrossRef
8.
go back to reference Lancer SR, Bowser EN, Hargis GK. The effect of growth hormone on parathyroid function in rats. Endocrinology. 1976;98:1289–93.CrossRef Lancer SR, Bowser EN, Hargis GK. The effect of growth hormone on parathyroid function in rats. Endocrinology. 1976;98:1289–93.CrossRef
9.
go back to reference Lund B, Eskildsen PC, Lund B, Norman AW, Sorensen OH. Calcium and vitamin D metabolism in acromegaly. Acta endocrinologica. 1981;96:444–50.CrossRef Lund B, Eskildsen PC, Lund B, Norman AW, Sorensen OH. Calcium and vitamin D metabolism in acromegaly. Acta endocrinologica. 1981;96:444–50.CrossRef
10.
go back to reference Sigurdsson G, Nunziata V, Reiner M, Nadarajah A, Joplin GF. Calcium absorption and excretion in the gut in acromegaly. Clin Endocrinol. 1973;2:187–92.CrossRef Sigurdsson G, Nunziata V, Reiner M, Nadarajah A, Joplin GF. Calcium absorption and excretion in the gut in acromegaly. Clin Endocrinol. 1973;2:187–92.CrossRef
11.
go back to reference Takamoto S, Tsuchiya H, Onishi T, et al. Changes in calcium homeostasis in acromegaly treated by pituitary adenomectomy. J Clin Endocrinol Metab. 1985;61:7–11.CrossRef Takamoto S, Tsuchiya H, Onishi T, et al. Changes in calcium homeostasis in acromegaly treated by pituitary adenomectomy. J Clin Endocrinol Metab. 1985;61:7–11.CrossRef
12.
go back to reference Nadarajah A, Hartog M, Redfern B, et al. Calcium metabolism in acromegaly. British medical journal. 1968;4:797–801.CrossRef Nadarajah A, Hartog M, Redfern B, et al. Calcium metabolism in acromegaly. British medical journal. 1968;4:797–801.CrossRef
13.
go back to reference Ezzat S, Melmed S, Endres D, Eyre DR, Singer FR. Biochemical assessment of bone formation and resorption in acromegaly. J Clin Endocrinol Metab. 1993;76:1452–7.PubMed Ezzat S, Melmed S, Endres D, Eyre DR, Singer FR. Biochemical assessment of bone formation and resorption in acromegaly. J Clin Endocrinol Metab. 1993;76:1452–7.PubMed
14.
go back to reference Pines A, Olchovsky D. Urolithiasis in acromegaly. Urology. 1985;26:240–2.CrossRef Pines A, Olchovsky D. Urolithiasis in acromegaly. Urology. 1985;26:240–2.CrossRef
15.
go back to reference Halse J, Haugen HN. Calcium and phosphate metabolism in acromegaly. Acta endocrinologica. 1980;94:459–67.CrossRef Halse J, Haugen HN. Calcium and phosphate metabolism in acromegaly. Acta endocrinologica. 1980;94:459–67.CrossRef
16.
go back to reference Bijlsma JW, Nortier JW, Duursma SA, Croughs RJ, Bosch R, Thijssen JH. Changes in bone metabolism during treatment of acromegaly. Acta endocrinologica. 1983;104:153–9.CrossRef Bijlsma JW, Nortier JW, Duursma SA, Croughs RJ, Bosch R, Thijssen JH. Changes in bone metabolism during treatment of acromegaly. Acta endocrinologica. 1983;104:153–9.CrossRef
17.
go back to reference Spanos E, Pike JW, Haussler MR, et al. Circulating 1alpha,25-dihydroxyvitamin D in the chicken: enhancement by injection of prolactin and during egg laying. Life sciences. 1976;19:1751–6.CrossRef Spanos E, Pike JW, Haussler MR, et al. Circulating 1alpha,25-dihydroxyvitamin D in the chicken: enhancement by injection of prolactin and during egg laying. Life sciences. 1976;19:1751–6.CrossRef
18.
go back to reference Boass A, Toverud SU, McCain TA, Pike JW, Haussler MR. Elevated serum levels of 1alpha, 25-dihydroxycholecalciferol in lactating rats. Nature. 1977;267:630–2.CrossRef Boass A, Toverud SU, McCain TA, Pike JW, Haussler MR. Elevated serum levels of 1alpha, 25-dihydroxycholecalciferol in lactating rats. Nature. 1977;267:630–2.CrossRef
19.
go back to reference Mazziotti G, Biagioli E, Maffezzoni F, et al. Bone turnover, bone mineral density, and fracture risk in acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2015;100:384–94.CrossRef Mazziotti G, Biagioli E, Maffezzoni F, et al. Bone turnover, bone mineral density, and fracture risk in acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2015;100:384–94.CrossRef
20.
go back to reference Eller-Vainicher C, Falchetti A, Gennari L, et al. DIAGNOSIS OF ENDOCRINE DISEASE: Evaluation of bone fragility in endocrine disorders. Eur J Endocrinol. 2019;180:213–32. Eller-Vainicher C, Falchetti A, Gennari L, et al. DIAGNOSIS OF ENDOCRINE DISEASE: Evaluation of bone fragility in endocrine disorders. Eur J Endocrinol. 2019;180:213–32.
21.
go back to reference Anthony JR, Ioachimescu AG. Acromegaly and bone disease. Curr Opin Endocrinol Diabetes Obes. 2014;21:476–82.CrossRef Anthony JR, Ioachimescu AG. Acromegaly and bone disease. Curr Opin Endocrinol Diabetes Obes. 2014;21:476–82.CrossRef
Metadata
Title
Acromegaly and non‐parathyroid hormone‐dependent hypercalcemia: a case report and literature review
Authors
Shaomin Shi
Lan Zhang
Yerong Yu
Chun Wang
Jianwei Li
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2021
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-021-00756-z

Other articles of this Issue 1/2021

BMC Endocrine Disorders 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.